Data Sheet (Cat.No.T16273)

TargetMol
A DRUG SCREENING EXPERT

Napsagatran hydrate

Chemical Properties



CAS No.:	159668-20-9
Formula:	C26H36N6O7S
Molecular Weight:	576.67
Appearance:	N/A
Storage:	0-4℃ for short term (days to weeks), or -20℃ for long term (months).

Biological Description

Description	Napsagatran hydrate is a novel and specific inhibitor of thrombin.
Targets(IC_{50})	Thrombin: None
In vitro	Napsagatran causes a dose-dependent prolongation of the activated partial thromboplastin time (aPTT) and prothrombin time (PT) that is evident 15 min after administration of the bolus of Napsagatran. Napsagatran also reduces the time to reperfusion in a dose-dependent manner and delays or prevents reocclusion. The decreasing intracellular amount and efflux of the compound from the cells into the medium is measured [1][2].
In vivo	Statistical analysis confirms that thrombus growth in the placebo and AP-1 treated rabbits is not different. In contrast, the reduction of 125I-fibrinogen incorporation by Napsagatran is statistically different from the placebo group (P<0.01). After the first hour of drug administration (from 0 to 60 min), the incorporated radioactivity into thrombi increased from baseline by 73±13, 67±22, and 32±10% in placebo, AP-1, and Napsagatran-treated rabbits, respectively.[3].

Solubility Information

Solubility	< 1 mg/ml refers to the product slightly soluble or insoluble

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.734 mL	8.67 mL	17.341 mL
5 mM	0.347 mL	1.734 mL	3.468 mL
10 mM	0.173 mL	0.867 mL	1.734 mL
50 mM	0.035 mL	0.173 mL	0.347 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 ℃ for 6 months; - 20 ℃ for 1 month. Please use it as soon as possible.

Reference

1. Pratico D, et al. Interaction of a thrombin inhibitor and a platelet GP IIb/IIIa antagonist in vivo: evidence thatthrombin mediates platelet aggregation and subsequent thromboxane A2 formation during coronary thrombolysis. J Pharmacol Exp Ther. 1997 Jun;281(3):1178-85.

2. Lundquist P, et al. Prediction of in vivo rat biliary drug clearance from an in vitro hepatocyte efflux model. Drug Metab Dispos. 2014 Mar;42(3):459-68.

3. Himber J, et al. Inhibition of tissue factor limits the growth of venous thrombus in the rabbit. J Thromb Haemost. 2003 May;1(5):889-95.

Tel:781-999-4286 E-mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481